These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38943034)

  • 21. Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4-5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study.
    Lin Y; Chao TF; Tsai ML; Tseng CJ; Wang TH; Chang CH; Lin YS; Yang NI; Chu PH; Hung MJ; Wu VC; Chen TH
    J Thromb Thrombolysis; 2024 Jan; 57(1):89-100. PubMed ID: 37605063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Decade of Experience.
    Spruit JR; de Vries TAC; Hemels MEW; Pisters R; de Groot JR; Jansen RWMM
    Drugs Aging; 2024 Sep; 41(9):725-740. PubMed ID: 39141209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists.
    Sakai T; Motoki H; Fuchida A; Takeuchi T; Otagiri K; Kanai M; Kimura K; Minamisawa M; Yoshie K; Saigusa T; Ebisawa S; Okada A; Kitabayashi H; Kuwahara K
    Heart Vessels; 2022 Jul; 37(7):1232-1241. PubMed ID: 35064298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis.
    Li D; Chang P; Zhang H; Bai F; Wu Q
    Eur J Clin Pharmacol; 2023 Apr; 79(4):461-471. PubMed ID: 36795127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial.
    De Vriese AS; Caluwé R; Van Der Meersch H; De Boeck K; De Bacquer D
    J Am Soc Nephrol; 2021 Jun; 32(6):1474-1483. PubMed ID: 33753537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease.
    Douros A; Cui Y; Platt RW; Filion KB; Sebastiani G; Renoux C
    Br J Clin Pharmacol; 2022 Mar; 88(3):994-1009. PubMed ID: 34409636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation.
    Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L
    JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions.
    Kirchmayer U; Narduzzi S; Mayer F; Tuccori M; Leoni O; Belleudi V; Di Martino M; Lallo A; Addis A; Davoli M
    Recenti Prog Med; 2019 Apr; 110(4):195-202. PubMed ID: 31066365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease.
    Bhatia HS; Bailey J; Unlu O; Hoffman K; Kim RJ
    Pacing Clin Electrophysiol; 2019 Nov; 42(11):1463-1470. PubMed ID: 31599969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
    Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
    J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
    [No Abstract]   [Full Text] [Related]  

  • 31. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
    Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
    Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.
    Harrington J; Carnicelli AP; Hua K; Wallentin L; Patel MR; Hohnloser SH; Giugliano RP; Fox KAA; Hijazi Z; Lopes RD; Pokorney SD; Hong H; Granger CB
    Circulation; 2023 Jun; 147(23):1748-1757. PubMed ID: 37042255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Zirlik A; Bode C
    J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
    Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists.
    He N; Dell'Aniello S; Zhai S; Suissa S; Renoux C
    Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):389-397. PubMed ID: 32722764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct oral anticoagulants versus vitamin K antagonists: Which one is more effective in atrial fibrillation.
    Khodadadiyan A; Jazi K; Bazrafshan Drissi H; Bazroodi H; Mashayekh M; Sadeghi E; Gholamabbas G; Bazrafshan M; Rahmanian M
    Perfusion; 2024 Oct; 39(7):1286-1294. PubMed ID: 37697799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
    de Jong LA; Gout-Zwart JJ; van den Bosch M; Koops M; Postma MJ
    J Med Econ; 2019 Apr; 22(4):306-318. PubMed ID: 30614320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulants' Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study.
    Frappé P; Cogneau J; Gaboreau Y; Abenhaïm N; Bayen M; Guichard C; Jacquet JP; Lacoin F; Liébart S; Bertoletti L; Bosson JL;
    Ann Fam Med; 2020 Mar; 18(2):131-138. PubMed ID: 32152017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.